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Abstract: Radical cure of infectious disease lies in the principle that the contagion is   eliminated 
and its propagation within the body is stopped. By understanding the true mechanisms of human 
immunodeficiency virus (HIV) infection, effective cure is possible. Vertical research in HIV/
acquired immunodeficiency syndrome (AIDS) has produced much advanced data about its nature 
without discovering a true cure, implying that the infective concept may have been missed. 
Overall, current interventions have had a significant impact on the pandemic, but they definitely 
have not achieved a cure. Given that modern research has already provided almost all significant 
data on HIV/AIDS, this inevitably means that understanding of the HIV and AIDS mechanism 
in the human body and population is less than sufficient. This paper advances a new concept 
using the available scientific data in an attempt to open a new frontier in HIV research.
Keywords: human immunodeficiency virus, HIV, acquired immunodeficiency syndrome, 
AIDS, viral sequestration
Introduction
Human immunodeficiency virus (HIV) is a lentivirus, infection with which causes 
acquired immunodeficiency syndrome (AIDS)1,2 in humans, with progressive failure 
of the immune system, allowing life-threatening opportunistic infections and cancers 
to attack the body. Infection occurs by body fluid contact, ie, blood, semen, vaginal 
fluid, pre-ejaculate, and breast milk. The virus is present as both free virus particles 
and virus within infected cells in these fluids. The four main routes of transmission 
are unsafe sex, contaminated needles, breast milk, and perinatal transmission.
HIV infection in humans is classified as pandemic by the World Health 
  Organization. From its recognition in 1981 through to 2006, AIDS killed more than 
25 million people, with per capita infection of about 0.6% of the world’s   population.3 
Estimated mortality from AIDS in 2009 has been put at 1.8 million persons, of 
whom approximately 260,000 were children.4 New infections in the same year were 
estimated at 2.6 million. The AIDS pandemic has particularly ravaged Sub-Saharan 
Africa, with disproportionately large numbers of deaths, slowing economic growth and 
exacerbating poverty levels.5 Use of antiretroviral therapy, particularly the so-called 
highly active antiretroviral therapy (HAART), reduces both mortality and morbidity 
associated with HIV infection.6 Expanded antiretroviral therapy programs since 2004 
have reduced AIDS deaths and new infections in many parts of the world,4 although 
universal access to HAART and the optimal timing for initiation remain severely con-
strained, especially in Sub-Saharan Africa. Short-term and long-term adverse effects 
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associated with use of HAART are of major clinical concern, 
impacting negatively on the quality of lives of patients under 
treatment. It is also noteworthy that, despite HAART, patients 
require more intensive health care and nutrition programs 
in the stages immediately after initiation of treatment. The 
overall cost of lifelong antiretroviral therapy is constrained 
by inadequate funding, with many countries relying on 
donor support, meaning sustainability of these programs 
cannot be guaranteed. Compliance with HAART can be 
compromised by adverse effects, opportunity, cost, culture, 
and ignorance, thus presenting the challenge of emergence of 
HIV strains resistant to currently available antiretroviral 
therapy.   Preventive measures, such as awareness campaigns, 
  prevention of mother to child transmission, and safe sex, have 
played a significant role in the fight against AIDS. However, 
these alone have not been demonstrated to decrease the rate of 
new infections significantly, because an estimated 2.6 million 
people were newly infected in 2009.4 Although the natural 
course of the AIDS epidemic might be expected, as is the 
case with other epidemics, to ameliorate with time, the high 
statistics of new infections and mortality show otherwise.
The principal target cells of HIV in the human body are 
CD4+ T lymphocytes, macrophages, and dendritic cells.7 
AIDS is caused by a drastic reduction in CD4+ T lympho-
cytes to low critical levels whereby cell-mediated immunity 
is compromised and eventually lost. The CD4+ T lymphocyte 
count is diminished through direct viral killing of infected 
cells, increased rates of apoptosis in infected cells, and killing 
of infected CD4+ T cells by CD8 cytotoxic lymphocytes that 
recognize infected cells.
Untreated HIV infection in most individuals eventually 
develops into AIDS.8 Death is mostly due to opportunistic 
infections or malignancies associated with the progressive 
failure of the immune system.9 Individual variability of 
HIV progression to AIDS is attributed to viral, host, and 
  environmental factors, with most cases occurring within   
10 years of HIV infection.10,11 Antiretroviral therapy increases 
the life expectancy from an untreated mean of one year12 to 
an average survival time with antiretroviral therapy of more 
than 5 years as of 2005.13
Relevant virology
HIV is a member of the genus Lentivirus14 and part of the 
Retroviridae family.15 It is transmitted as a single-stranded, 
positive-sense, enveloped virus. On entry into the target cell, 
the viral RNA genome is reverse-transcribed into double-
stranded DNA by a virally encoded reverse transcriptase 
that is transported along with the viral genome in the 
virus particle. Importation of the resulting viral DNA into 
the host cell nucleus and integration into the cellular DNA 
by a virally encoded integrase and host cofactors follow.16 At 
this stage, it has been proposed that the virus may become 
latent, allowing it and its host cell to avoid detection by the 
immune system for an indeterminate time. Alternatively, 
the virus is transcribed, producing new RNA genomes and 
viral proteins that are packaged and released from the cell 
as new virus particles that begin the replication cycle anew. 
Two subtypes of HIV have been characterized, ie, HIV-1 
and HIV-2. HIV-1 was the one initially discovered and has 
been shown to be more virulent, more infective, and most 
widespread. HIV-2 is largely confined to West Africa due to 
its lower transmissibility.17,18
Stages of HIV infection
Primary stage
Following exposure to an infective load of HIV , the pri-
mary stage establishes itself. Symptoms in most individu-
als (80%–90%) during this stage include an influenza or 
mononucleosis-like illness called acute HIV infection, that 
most often includes fever, lymphadenopathy, pharyngitis, 
rash, myalgia, malaise, and mouth and esophageal sores, and 
may also include (albeit less commonly) headache, nausea 
and vomiting, an enlarged liver and/or spleen, weight loss, 
thrush, and neurological symptoms. Infected individuals 
may experience all, some, or none of these symptoms. The 
average duration of the illness is 28 days, and it usually lasts 
at least a week.19
This is the seeding stage when the virus establishes itself 
in the host system, and is marked with rigorous host immune 
resistance, as evident in first-line response symptoms that 
are generally similar to the body’s reaction to many other 
infections. A period of rapid viral replication ensues, lead-
ing to an abundance of virus in the peripheral blood, with as 
many as several million virus particles reached per milliliter 
of blood.20
Acute viremia is accompanied by a marked drop in the 
numbers of circulating CD4+ T cells and is seen in virtu-
ally all patients. It is accompanied by activation of CD8+ T 
cells which kill HIV-infected cells and subsequent antibody 
production or seroconversion. The CD8+ T cell response is 
thought to be important in controlling virus levels, which 
peak and then decline, as the CD4+ T cell counts rebound. 
CD8+ T cell response has been linked to slower disease pro-
gression and a better prognosis, although it does not eliminate 
the virus.21 Attempts have been made to prevent infection at 
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victims and children with a perinatal exposure risk, with 
encouraging results.
Secondary (latency) stage
The latency period lasts from 2 weeks to 20 years or more, 
depending on a variety of factors. Its hallmark is the absence 
of symptoms or few symptoms, depending on individuals. 
The viral load is initially reduced, but assumes a varying pro-
file with time, generally increasing in geometric   progression. 
HIV is active within the lymph nodes, which typically 
become persistently swollen in response to large amounts 
of virus that become trapped in the follicular dendritic cell 
network.22 The surrounding tissues that are rich in CD4+ 
T cells may also become infected, and viral particles accu-
mulate both in infected cells and as free virus.   Individuals 
who are in this stage remain infectious. During this time, 
CD4+ CD45RO+ T cells carry most of the proviral load.23 
It has been shown that antiretroviral therapy started during 
this stage significantly improves survival, as compared with 
deferred therapy.24,25
AIDS
The final stage of HIV infection, ie, AIDS, is characterized by 
low CD4+ T cell counts with various opportunistic infections, 
cancers, and other conditions, leading to systems failure and 
death. Opportunistic or pathogenic infections and cancers 
in AIDS increase and worsen with falling CD4 counts, and 
fail to respond to known effective treatment because of 
reduced or absent cell-mediated immunity, which is normally 
ultimately responsible for any antimicrobial cure. Without 
treatment, patients will eventually die. HAART initiated early 
can lead to remarkable improvement in prognosis and even 
keep individuals healthy for indeterminate periods. Although 
HAART has been shown to reduce viral loads in the circula-
tion to undetectable levels, it cannot eradicate the virus from 
the body, because its withdrawal leads to a rebound increase 
in viral load and progression to AIDS.
HIV controllers or long-term nonprogressors who retain 
high levels of CD4+ T cells without antiretroviral therapy 
and have a detectable viral load will eventually progress to 
AIDS without treatment. Elite suppressors, on the other hand, 
maintain CD4+ T cell counts and also have low or clinically 
undetectable viral load without antiretroviral treatment, 26,27 
suggesting they may have a genetic variation enabling them 
to control the virus even though they cannot eliminate it. HIV 
infects various cells, including CD4+ T cells, macrophages, 
and microglial cells. HIV-1 entry to macrophages and CD4+ 
T cells is mediated through interaction of virion envelope 
glycoproteins with the CD4 molecule on target cells and also 
with chemokine coreceptors.28
Vaccination and therapy
Immunomodulatory genes characterized to bear signifi-
cance in control of HIV replication have led to a search 
for immunotherapy that may assist in the recovery of the 
immune system.29,30 It has been demonstrated that the immune 
response in chronic HIV is down regulated by a genetic 
mechanism in the face of persistent infection. This has led 
to investigation of whether reversing this down regulation 
by gene therapy would provide any advantage in the fight 
against HIV infection.
A vaccine that is a combination of two previously unsuc-
cessful vaccine candidates (ALVAC-HIV and AIDSVAX) 
was reported in September 2009 to have resulted in a 30% 
reduction in infections in a trial conducted in Thailand.31,32
HAART administered immediately after exposure, 
referred to as post exposure prophylaxis, is believed to reduce 
the risk of infection if started as quickly as possible.33 Early 
treatment of HIV-infected people with HAART protected 
96% of partners from infection.34
A 40-year-old HIV-positive man was given a stem cell 
transplant as treatment for acute myelogenous leukemia, 
with the donor chosen for being homozygous for a CCR5-
∆32 mutation that confers resistance to HIV infection.35,36 
After 20 months without antiretroviral drug treatment, it 
was reported that HIV levels in the recipient’s blood, bone 
marrow, and bowel were below the limit of detection.36 The 
virus remained undetectable for at least 3 years after the first 
transplant.37
Pillars of faith
Does the latency stage of HIV infection 
involve sequestration of virus beyond 
activity of the immune system?
To answer this question, there is a need to look at the stages 
of HIV infection. In the primary stage, there is body fluid 
contact, ie, its introduction into the general body fluid and 
circulation compartment, with infection of immediately 
available target cells. Research has shown that the main 
routes of HIV transmission are unsafe sex, contaminated 
needles, breast milk, and perinatal transmission, all of which 
must involve fluid contact. This means the virus at this stage 
has to seed by rapid replication in the immediately available 
target cells in order to attain sufficient populations to cause 
effective infection elsewhere. That the infective viral load HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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is very small compared with the levels of virus found at the 
peak of primary infection further demonstrates this point. 
The body mounts an aggressive immune response at this 
stage, as seen in the various symptoms of primary infection. 
This means that the immune system is able to recognize 
the virus at this stage and initiate nonspecific, then specific 
responses directed at containing the infection. The fact that 
primary symptoms abate after some time suggests that the 
immune system has indeed contained the primary infection, 
and secondary infection has a source other than the initial 
one. In patients given post exposure HAART, such as rape 
victims and neonates at risk of perinatal transmission in 
prevention of mother to child transmission, statistics show 
that effective transmission is drastically reduced, pointing 
to failure of primary infection to proceed to secondary 
  infection. These groups do not contract long-term infection 
even though they have had exposure, meaning contamina-
tion of the general circulation compartment alone is not 
sufficient to confer chronic infection. HAART prevents 
the rapid initial replication needed to achieve populations 
required for effective chronic infection and, in concert with 
the aggressive immune responses; the virus is totally elimi-
nated from the general circulation. Transmission of the virus 
from the mother to the child occurs in utero, intrapartum, 
or through breast feeding. In the absence of strategies for 
prevention of mother to child transmission, the transmis-
sion rate up to birth between the mother and child is about 
25%.38 Using combination HAART and cesarean section, 
the risk is reduced to as low as 1%.38 Exclusive breast feed-
ing and provision of extended prophylactic HAART to the 
infant are also effective in prevention of transmission.39 
According to Joint United Nations Programme on HIV and 
AIDS estimates, 430,000 children were infected worldwide 
in 2008 (19% of all new infections), primarily by this route, 
and 65,000 infections were avoided through the provision of 
antiretroviral prophylaxis to HIV-positive women.40
In a bone marrow transplant patient who was shown to be 
totally rid of the virus, only the bone marrow was changed 
to confer resistance to re-infection, even in the presence of 
other target cells in the general circulation, suggesting bone 
marrow is indeed a different and unique compartment in the 
process of HIV infection. The HIV was not removed from the 
patient’s general circulation, dendritic cells, macrophages, 
or circulating long-life T memory lymphocytes. It was the 
reserve area of bone marrow that was changed, depriving the 
infection of a critical source of re-infection, thus allowing 
the immune system to clear the virus summarily from the 
“open” target cells. This principle is further supported by the 
fact that there exists a biological barrier in the bone marrow 
function of lymphocytogenesis. Compartmentalization in 
the bone marrow itself is well known, as is the biological 
blood-bone marrow barrier. The long period of latency of 
HIV infection, spanning on average 10 years to the onset 
of AIDS, represents the period when the reserve infection, 
although active, has not reached populations sufficient to 
decimate CD4+ T lymphocyte numbers. This means the 
virus has dodged the host defenses and is safely established, 
progressively replicating and releasing new particles into the 
general circulation. Latency means the virus cannot cause a 
sufficient decline in CD4+ T cells to cause AIDS, but it is 
still there in significant and increasing amounts, and yet it is 
able to avoid causing a remarkable host immune response 
on the scale seen at the primary infection stage. It has been 
suggested that the human immune modulation gene down 
regulates the response to a sustained viral presence, and 
that disabling this gene may reactivate aggressive immune 
reactivity that could control the progression to AIDS. It is 
apparent in this regard that HIV has found “safe” host cells 
from which it keeps re-infection of the whole host system 
going in spite of any immune mechanisms.   Treatment using 
HAART may reduce this reserve infection, but being a 
competitive inhibition process, it cannot eliminate it. The 
virus sequestered in these safe cells is out of reach of the 
immune system and cannot be eradicated, whereas the virus 
released into the general circulation is controlled by HAART 
and eliminated by host immune mechanisms. This is why 
cessation of HAART leads to resurgence of viral loads 
and progression to AIDS without the initial symptoms of 
the primary stage. Thus, it can be inferred that there is no 
biological latency period in HIV infection, as suggested by 
proponents of the latent stage.
From the above, it is logical to conclude that the latency 
stage of HIV infection occurs when the immune system has 
subdued the viral infection in the general circulation, and 
chronic infection ensues because, by this time, the virus has 
already been sequestered in the bone marrow and established 
reserve infection.
Does there exist such a unique 
compartment in human physiology  
where the HIV virus might hide  
in the form of reserve infection?
There is in fact a physiological barrier between bone mar-
row and blood which prevents immature lymphocytes from 
entering the circulation. The bone marrow itself is composed HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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of distinct biological compartments. This barrier is unique 
in that, unlike the blood-brain barrier, it restricts biological 
systems rather than chemical or structural systems. Because 
only mature lymphocytes can enter the circulation, it is pos-
sible that this is done to protect immature cells from some 
aspects in the general circulation. One such aspect could 
be the CD8 cytotoxic lymphocyte, which is credited with 
destruction of infected or malfunctioning cells, a process 
which results in the final eradication of any intracellular 
contagion and cancer. This system may also protect the 
HIV virus, which infects protected immature lymphocytes. 
Because lymphocytes are continuously produced to meet 
body demand according to biological feedback regulation, 
infection by the virus would not deplete all immature lym-
phocytes until such time when the viral load is overwhelm-
ingly high, which can take a long time considering the 
dynamics of cell formation and the viral replication cycle, 
as well as the fact that not all infected cells are killed by 
apoptosis or direct viral action. It is proposed that depletion 
of CD4+ T lymphocytes occurs not only as a direct result of 
viral infection in the general circulation, but also as a result 
of reduced production due to infection of immature lympho-
cytes in the bone marrow. By transplantation of donor bone 
marrow resistant to infection, the patient described earlier 
was conferred with the ability to increase his CD4+ count 
despite presence of infection in other cells of the body. The 
new lymphocytes were not susceptible to infection, even 
when they entered circulation, while the older group of 
infected target cells was killed by apoptosis or CD8 action. 
The infection was thus eventually cleared by the immune 
system without the use of drugs.
The reason why it has proved difficult to develop an HIV 
vaccine can be explained in this context. Primary infection 
in a vaccinated individual still results in enough viral load to 
attain bone marrow sequestration, although it may be remark-
ably lower than the load in a non-vaccinated individual. The 
viral reserve in the bone marrow is able to avoid the ultimate 
step in elimination of contagions by staying out of the scope 
of CD8 cytotoxic lymphocytes, and probably other immune 
mechanisms necessary for elimination.
It can be concluded here that the bone marrow com-
prises a unique physiological compartment in which HIV is 
sequestered to maintain chronic infection in humans. This 
sequestration occurs after successful primary infection in 
the period before the immune system is able to subdue the 
initial infection. Subsequent infections attain levels sufficient 
to reach viral sequestration, hence re-infection with different 
chronic strains in the same patient.
Is it possible to eliminate HIV infection 
using currently available antiretroviral 
therapy in the absence of reserve 
infection?
Viral replication rates for primary HIV infection are not 
sustained into the latency stage. If such rates could be 
  sustained, then the primary infection itself would be lethal 
and there would be no latency stage. In post exposure 
HAART, it is possible to eliminate the infection at the 
onset by prevention of progress to sequestration. In the 
bone marrow transplant HIV patient described earlier, 
elimination of viral reserve led to elimination of the 
virus elsewhere, even without further use of HAART. 
  Vaccination can be possible if the immune system is able 
to prevent initial multiplication, dissemination, and seques-
tration of the virus. This can be demonstrated by the fact 
that some vaccine trials have shown a measure of success, 
and depending on the site and dosage of initial infection, 
the immune system may be able to eliminate the infection 
before sequestration.
It is logical to conclude that the immune system can 
eliminate HIV infection in the absence of reserve infection. 
HAART can prevent formation of reserve infection when 
given before viral sequestration has occurred, thus allowing 
the immune system to eliminate primary infection.
What are the options that could be 
pursued to clear the said reserve 
infection and deal the virus the ultimate 
blow?
Infection of any kind cannot be totally eliminated by drugs, 
which, regardless of their efficacy, act by competitive inhi-
bition of cellular processes. A functional immune system is 
critical for the radical eradication of a contagion. This can be 
demonstrated by considering the progression of infection in 
immunocompromised patients. HIV elimination would simi-
larly require a functional immune system even when effective 
drug therapy is available. Even though current HAART is 
effective in the control of infection in all target cells of the 
body, to achieve viral elimination, the cells bearing reserve 
infection in the bone marrow must be targeted and eliminated 
by the immune system without compromising the functional 
role of the blood-bone marrow barrier.
Research can be focused on achieving elimination or 
preventing the formation of reserve infection. Obviously if 
this is the point that has been missed in understanding of the 
infective circle of HIV , then herein lies the solution. Such a HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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line of research is also likely to obtain more new information 
useful in medicine and science.
One of the questions to be addressed would be whether 
or not currently used drugs penetrate bone marrow in thera-
peutically significant amounts, and whether any changes or 
development can positively enhance activity within the viral 
reserve. Another line of research would be to determine the 
feasibility of implanting a remedy in the bone marrow, or 
breaching the bone marrow barrier for a period to allow full 
combat by the immune system. However, these will be sub-
jects of future papers. It is possible to verify the veracity of 
these hypotheses by, for example, conducting animal-based 
research using similar infections such as simian immunode-
ficiency virus in monkeys.
Infective story of HIV
Upon entry of HIV into the system of an individual, the 
virus infects the immediately available target cells at the 
point of contact. It proceeds to replicate rapidly in these 
cells, with new viruses released and thus quickly infect-
ing other available target cells. The increasing viral load 
disseminates via the circulation system, ie, the blood and 
lymphatic system, seeding and establishing more foci with 
replication. The initial rate of replication is high, and the 
resulting viral load increases in geometric progression. 
This leads to a rapid decline in CD4+ T lymphocytes 
as more cells are infected and die, probably because the 
feedback-mediated increase in production does not com-
mence immediately or at a rate comparable with the rate of 
destruction. Also, at this point, the immune system recog-
nizes the presence of infection and initiates a general non-
specific response, leading to the symptoms seen at primary 
infection. In the meantime, as viral replication continues, 
the immune system evaluates the virus successfully and 
initiates specific responses, which include production of 
specific antibodies (seroconversion) and surface antigen 
marking of infected cells for immune destruction. With 
the onset of the specific immune response, the infection is 
rapidly cleared and there is a rapid reduction in the viral 
population, with reduced infection of new target cells. 
There is also a rebound increase in CD4+ T lymphocytes 
as a result of increased feedback-mediated production as 
well as reduced infection of new cells.
However, before the immune system is ready to mount 
the specific response described above, the viral population 
peaks in the circulation and is widely disseminated in the 
body, with some becoming sequestered in the bone marrow 
compartment where the immune mechanism is unable to 
eliminate it. Although the immune system tries to eradicate 
the infection from the general circulation completely, the 
infection is maintained by constant supply of new virus 
from the reserve sequestered in the bone marrow. This is the 
chronic stage, and the peripheral viral load depends mainly 
on the dynamics of viral replication and immune action in 
the blood.
Immunomodulators downgrade the specific immune 
response against HIV over time, allowing the viral load to 
increase slowly and steadily, until it reaches a point when 
CD4+ T lymphocyte production cannot match destruction by 
infection. The CD4 count then slowly and steadily declines, 
along with a decline in cell-mediated immunity. When the 
CD4 count reaches a critical minimum at which cell-mediated 
immunity can no longer provide adequate protection, AIDS 
sets in.
Initiation of HAART immediately after infectious 
inoculation of HIV can abort chronic infection as long as it 
is done before viral replication has led to dissemination and 
sequestration of the virus in the bone marrow. In this case, 
the immune system completely eliminates any residual virus 
from the general circulation.
When bone marrow from a resistant individual is trans-
planted into an AIDS patient whose own bone marrow has 
been removed, the immune response is able to eliminate the 
virus from the body because of the absence of a sequestered 
reserve to maintain chronic infection.
It is impossible to achieve vaccination against HIV 
infection because, as with all vaccinations, a milder form 
of infection follows exposure in a vaccinated individual. 
This mild infection in the case of HIV is still sufficient to 
cause dissemination and bone marrow sequestration, hence 
chronic infection.
In discordant couples, when the resistant partner gets 
the first primary infection, that partner can transmit it to the 
susceptible mate during the initial period of infection but 
proceed to eliminate the virus from their own bodies because 
of absence of sequestration, while their partner develops 
chronic infection. Subsequent exposures lead to development 
of immune resistance in the resistant partner and do not cause 
primary infection due to absence of viral sequestration.
Re-infection in patients with chronic infection is pos-
sible because although initial infection provides protection 
against subsequent attacks, cell-mediated immunity in these 
individuals is usually reduced, allowing new infection to 
reach a population load adequate for sequestration in the HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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bone marrow before it is subdued. Furthermore, a milder 
form of infection which usually follows exposure of immune 
individuals may still attain enough viral loads to cause 
sequestration.
Prevention of viral sequestration or elimination of reserve 
infection is the key to attaining a radical cure for HIV. 
Although post exposure HAART can prevent viral sequestra-
tion, its use in the general population would present enormous 
logistical challenges, rendering it impractical, in addition to 
being of no use in those with chronic infection. Therefore, 
the focus should be on elimination of reserve infection in 
infected individuals. Vaccines could be designed not just to 
protect against infection but to act as exposure alerts or alarm 
systems to enable effective post exposure HAART.
There cannot be any errors in these general propositions 
because the line of thinking is based on pure logic. However, 
variations in the results of specific aspects of this analysis 
are possible, although not in a manner that could be expected 
to change the theory in a radical way. Furthermore, should 
investigation radically change the flow of theory, it would 
still be credited for spurring that line of research.
Summary
Long-term HIV infection occurs when the virus is 
  sequestered in “safe” cells in a unique body compartment 
where it forms a “reserve infection” and avoids eradication 
by the host immune system, and maintains general infec-
tion by continuous re-infection from this site. This unique 
compartment is the bone marrow. The latent stage of HIV 
infection is in fact an active stage in which reserve infection 
sequestered in “safe” cells of the bone marrow compartment 
continuously release new virus particles into the circulation, 
and AIDS occurs when the rate of viral production exceeds 
T cell replacement, leading to a gradual decline in CD4 count. 
Using available scientific data, knowledge, and logic, it is 
possible to demonstrate existence of these “safe” cells within 
the bone marrow as a unique physiological compartment, to 
show existence of a critical HIV reserve in these cells during 
chronic infection, and to show that absence or removal of the 
reserve infection leads to viral eradication, and thus provide 
the basis for new research along these lines. The explanations 
for various phenomena in HIV infection, such as discordant 
partners, re-infection, vaccine failure, and long periods of 
apparent latency, lie in the theory of critical reserve infec-
tion sequestered in the “safe” cells of the bone marrow. The 
human immune system can eliminate HIV infection from 
the general target cells of the body if viral sequestration is 
prevented or reserve infection is removed from its site of 
safe sequestration in the bone marrow.
This theory discredits the perception that long-term 
HIV infection occurs at the onset of primary infection 
and is maintained within the general target cells, with the 
host immune system and current drugs being unable to 
eliminate it effectively. That HIV maintains infection by 
passive latency, whereby some of the integrated viral DNA 
remains dormant within the nucleus of the host cell, retain-
ing a capability to activate a full cycle of viral replication 
in the future. That no unique “safe” cells or compartment in 
the body where reserve HIV infection is sequestered away 
from active host immunity or drugs can be demonstrated 
using the available scientific data and logic. That it is not 
possible to achieve a radical cure of HIV infection by focus-
ing research on the principle of safe cells for reserve HIV 
infection in the body. And that the human immune system 
cannot eliminate HIV infection from the general target cells 
under any circumstances.
Enough scientific information on HIV and AIDS has 
been gleaned from modern research to warrant comprehen-
sive intervention against the pandemic. Vertical research 
has revealed many important aspects of the virus and its 
relationship with the human body, to an extent approaching 
exhaustion, making it unlikely that we will unravel any more 
aspects of greater significance in the design of pharmacologi-
cal or other innovations than have already been achieved. 
By focusing new research in a different dimension, it is 
possible to utilize this information to open up new frontiers 
in the search for a cure for HIV infection. The proven and 
indisputable scientific information available to advance logic 
and propositions simply provides a means of convergence 
of knowledge gathered by documented research, so there is 
a real prospect of success and no possibility of controversy 
or scientific conflict. There is instead an opportunity for 
advancement of knowledge. Providing a backbone of scien-
tific theory can spur specific research that may provide further 
insight on aspects not considered before, contributing to a   
generation of new knowledge and development of effective   
interventions in HIV research.
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